We were grateful for the opportunity to attend and present at the AACR Annual Meeting last week, where three of our scientists highlighted some of the exciting work happening in our Vancouver lab.
March 28, 2023
Imagia Canexia Health announced that three abstracts highlighting the company’s new learnings and tools will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.
December 1, 2022
The holiday season is around the corner and we would like to inform everyone of our operation schedule over Christmas and New Year.
September 22, 2022
Appointment fortifies Imagia Canexia Health’s board with leading expertise in successfully scaling biopharma and diagnostics enterprises
June 15, 2022
Imagia Canexia Health, a genomics-based cancer treatment testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions, today announced the CE-IVD marking for its Imagia Canexia Health Insights Platform (ICHIP) to operate across Europe.
April 21, 2022
Vancouver, BC [April 21, 2022] – Canada’s Digital Technology Supercluster is excited to be
February 17, 2022
Merger includes C$20 million investment to accelerate access to genomics-based testing for cancer treatment by combining Canexia Health’s advanced molecular cancer solutions with Imagia Cybernetics’ healthcare and AI expertise
December 13, 2021
With a strategic investment from Canada’s Digital Technology Supercluster, a pilot project to bring ctDNA testing into the Canadian health system was launched in July 2020.
November 11, 2021
Liquid biopsy is a powerful tool for matching cancer patients with targeted therapies and for cancer recurrence monitoring.
November 4, 2021
The use of genomic profiling and testing in cancer is helping clinicians and patients better understand the key drivers of a patient’s tumour and inform more precise treatment decisions.
Every Imagia Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.